Zydus Lifesciences Limited has announced the launch of its Semaglutide injection in India under the brand names SEMAGLYN, MASHEMA and ALTERME, following the expiry of the product’s patent. The therapy has received approval from the Drug Controller General of India for the treatment of Type 2 Diabetes Mellitus and obesity, addressing two of the country’s fastest-growing health concerns.
The newly introduced therapy features a reusable multi-dose pen device, offering a practical alternative to conventional single-use injection pens. Patients undergoing dose adjustments often require multiple pens under existing treatment methods. The new device enables users to select varying dose strengths from a single pen, simplifying administration while improving adherence to prescribed regimens.
The Semaglutide injection will be available in a 15 mg/3 ml cartridge and manufactured at Zydus Biotech Park in Ahmedabad. The company has indicated that the average monthly cost of treatment will be approximately Rs. 2,200, making it more accessible for patients requiring long-term therapy.
India continues to face a rising burden of metabolic disorders. Data from the International Diabetes Federation indicates that nearly 89 million adults in the country are living with diabetes, accounting for over 10 percent of the adult population. Obesity levels have also increased sharply, with prevalence among women rising from 12.6 percent to 24 percent and among men from 9.3 percent to 22.9 percent over recent years. These trends underline the urgent need for effective and affordable treatment options.
Therapies based on GLP-1 are increasingly being recognized for their role in managing both diabetes and obesity. With this launch, Zydus aims to expand access to such therapies while improving patient convenience through device innovation.
Zydus Lifesciences operates as a global healthcare company engaged in the discovery, development, manufacturing and marketing of a wide range of therapies. The group employs more than 29,000 people worldwide, including a strong research team dedicated to advancing new treatments.
Over the past decade, the company has introduced multiple products across vaccines, biologics and novel therapies to address unmet medical needs. The introduction of Semaglutide marks another step in Zydus’ efforts to improve treatment accessibility and support better health outcomes across patient populations.